Sphera Funds Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Sphera Funds Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$71.7K	–	120
2025 Q3	$71.7K	Sell	10,000 -115,000	-92%	-$5.99M	0.02%	113
2025 Q2	$5.9M	Buy	+125,000	New	+$5.09M	1.38%	22

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sphera Funds Management's MLTX Position: Q4 2025 in Review

Sphera Funds Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 71,010 shares — an estimated $509K sold.

Sphera Funds Management first reported a position in MLTX in Q3 2025 and held it in 1 quarter. The position peaked at $509K in Q3 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

Sphera Funds Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
Sphera Funds Management sold 71,010 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $509K.
Sphera Funds Management first reported a position in MoonLake Immunotherapeutics in Q3 2025 and held it in 1 quarter.
Sphera Funds Management's MoonLake Immunotherapeutics position peaked at $509K in Q3 2025.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Sphera Funds Management's 13F filing for Q4 2025, filed 17 Feb 2026.